Leerink Partners analyst Andrew Berens reiterated a Hold rating on Agios Pharma (AGIO – Research Report) on April 29 and set a price target of $50.00. The company’s shares closed last Friday at $55.80, close to its 52-week high of $58.93.
According to TipRanks.com, Berens is a 4-star analyst with an average return of 9.7% and a 56.8% success rate. Berens covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Global Blood Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Agios Pharma with a $62.63 average price target, implying a 12.6% upside from current levels. In a report issued on April 30, Goldman Sachs also initiated coverage with a Hold rating on the stock with a $58.00 price target.
The company has a one-year high of $58.93 and a one-year low of $32.47. Currently, Agios Pharma has an average volume of 724.9K.
Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AGIO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.